Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 5—May 2006
Tuberculosis Special Section

Mycobacterium tuberculosis and Rifampin Resistance, United Kingdom

I-Ching Sam*1, Francis Drobniewski*Comments to Author , Philip More*, Melanie Kemp*, and Timothy Brown*
Author affiliations: *Health Protection Agency, London, United Kingdom

Main Article

Table 7

Sequence analysis of 10 discrepant rifampin-susceptibility results*

Sample no. Rifampin susceptibility
LiPA result Phenotypic result Conclusion after sequencing
1–3 Sensitive Resistant From the same patient; wild-type rpoB test region
4 Sensitive Resistant Mycobacterium bovis; wild-type rpoB test region
5–7 Resistant (DS4) Sensitive From the same patient; synonymous substitution (R528R) not associated with rifampin resistance
8 Resistant (DS1) Sensitive 2 genotypes present: wild-type (predominant) and mutant (L511P)
9 Resistant (R5) Sensitive S531L mutation; wild-type rpoB on retesting, thus likely laboratory error
10 Resistant (DS2) Sensitive D516A mutation; no high-level resistance when seen alone

*LiPA, line probe assay.

Main Article

1Current affiliation: University of Malaya, Kuala Lumpur, Malaysia

Page created: January 06, 2012
Page updated: January 06, 2012
Page reviewed: January 06, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.